CBS 2019
CBSMD教育中心
English

药物涂层球囊

科研文章

荐读文献

The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis Contemporary use of drug-coated balloons in coronary artery disease: Where are we now? Outcomes after drug-coated balloon treatment for patients with calcified coronary lesions Drug-eluting balloons in coronary interventions: the quiet revolution? Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: A Feasibility Study Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients Therapeutic Options for In-Stent Restenosis
|<< 1 2 3 4 5 >>|

Review Article2018 Nov 29.

JOURNAL：Catheter Cardiovasc Interv. Article Link

Outcomes with drug-coated balloons in small-vessel coronary artery disease

Megaly M, Rofael M, Saad M et al. Keywords: drug-coated balloons; drug-eluting balloons; small-vessel disease coronary disease

ABSTRACT

BACKGROUND - Percutaneous coronary intervention (PCI) of small-vessel coronary artery disease (SVD) is associated with increased risk of restenosis. The use of drug-coated balloons (DCBs) in SVD has received limited study.


OBJECTIVES - To assess the outcomes of DCB in the treatment of SVD compared with the standard of care.


METHODS - We performed a meta-analysis of all studies published between January 2000 and September 2018 reporting the outcomes of DCB versus other modalities in the treatment of de novo SVD.


RESULTS - Seven studies with 1,824 patients (1,938 lesions) were included (four randomized controlled trials and three observational studies). During a mean follow-up of 14.5 ± 10 months, DCBs were associated with a similar risk of target lesion revascularization (TLR) (OR: 0.99, 95% CI: 0.54, 1.84, P = 0.97) and major adverse cardiovascular events (MACE) (OR: 0.86, 95% CI: 0.51, 1.45, P = 0.57) compared with drug-eluting stents (DES). During a mean follow-up of 7 ± 1.5 months, DCBs were associated with a significantly lower risk of TLR (OR: 0.19, 95% CI 0.04-0.88, P = 0.03) and binary restenosis (OR: 0.17, 95% CI 0.08-0.37, P = <0.00001) compared with noncoated balloon angioplasty.


CONCLUSION - The use of DCBs in SVD is associated with comparable outcomes when compared with DES and favorable outcomes when compared with balloon angioplasty.

© 2018 Wiley Periodicals, Inc.

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top